Archives for May 31, 2006

← 2006

New help for UK drug makers to pass FDA inspection

By  Kirsty Barnes

RSSL Pharma Training has established three new courses to help UK pharmaceutical and medical device manufacturers prepare themselves for a plant inspection by the US Food and Drug Administration (FDA).

China the "land of opportunity" for stem cell research

By  Kirsty Barnes

China could be the first country to conduct human stem cell trials and presents a significant opportunity for Western companies who are brave enough to use this risky destination as a place to pursue this potentially lucrative sector of the biotech...

Wyeth blasted by the FDA over its Puerto Rico manufacturing plant

By  Gregory Roumeliotis

In a scathing letter to Wyeth, the US Food and Drug Administration (FDA) has vehemently criticised the drugmaker's manufacturing operations in Puerto Rico, accusing it of failing to report failures even when it was aware of them.

Pro Mach seeks retort and sterilisation capabilities

By  Gregory Roumeliotis

Pro Mach, one of the largest providers of packaging products, services and integrated solution sets in North America, has acquired Allpax Products, a manufacturer of sterilisation, material handling and automated control systems for the food, beverage...

Medidata gives boost to e-clinical data offerings

By  Kirsty Barnes

Medidata Solutions has opened a new clinical data centre and enlisted the help of consultancy firm C3i to provide its customers with faster and more secure electronic clinical trial support as demand for these services continues to increase.

PDI showing early signs of recovery

By  Kirsty Barnes

Troubled contract sales and marketing firm PDI has recently won a much-needed new sales contract and made two new top executive appointments as part of ongoing efforts to turn its flagging business around.

Xemplar moves to fill inhaler manufacturing gap

By  Kirsty Barnes

MAP Pharmaceuticals has awarded the manufacturing of the metered-dose components of its new inhaler devices to Xemplar, who is one of the few contract manufacturers in the world that can take on such a challenge and is now upping manufacturing...

Schweizerhall devotes to pharma

By  Gregory Roumeliotis

Determined to transform itself from a chemical distributor to a drug firm, Schweizerhall has sold its chemical business unit to Brenntag for SFr93m (€60m), allowing it to pay for financial obligations, invest in its pharma division, and even make...